Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism
- PMID: 28160670
- DOI: 10.1016/j.thromres.2017.01.007
Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism
Abstract
Importance: Unprovoked venous thromboembolism (VTE) can be the first manifestation of cancer. It is unclear if extensive screening for occult cancer including a comprehensive computed tomography (CT) scan of the abdomen/pelvis is cost-effective in this patient population.
Objective: To assess the health care related costs, number of missed cancer cases and health related utility values of a limited screening strategy with and without the addition of a comprehensive CT scan of the abdomen/pelvis and to identify to what extent testing should be done in these circumstances to allow early detection of occult cancers.
Participants and setting: Cost effectiveness analysis using data that was collected alongside the SOME randomized controlled trial which compared an extensive occult cancer screening including a CT of the abdomen/pelvis to a more limited screening strategy in patients with a first unprovoked VTE, was used for the current analyses.
Main outcomes and measures: Analyses were conducted with a one-year time horizon from a Canadian health care perspective. Primary analysis was based on complete cases, with sensitivity analysis using appropriate multiple imputation methods to account for missing data.
Results: Data from a total of 854 patients with a first unprovoked VTE were included in these analyses. The addition of a comprehensive CT scan was associated with higher costs ($551 CDN) with no improvement in utility values or number of missed cancers. Results were consistent when adopting multiple imputation methods.
Conclusions and relevance: The addition of a comprehensive CT scan of the abdomen/pelvis for the screening of occult cancer in patients with unprovoked VTE is not cost effective, as it is both more costly and not more effective in detecting occult cancer.
Keywords: Cancer screening tests; Oncology; Thromboembolism; Tomography, X-ray computed.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems.Thromb Res. 2018 Nov;171:97-102. doi: 10.1016/j.thromres.2018.09.050. Epub 2018 Sep 19. Thromb Res. 2018. PMID: 30268859 Clinical Trial.
-
Screening for Occult Cancer in Unprovoked Venous Thromboembolism.N Engl J Med. 2015 Aug 20;373(8):697-704. doi: 10.1056/NEJMoa1506623. Epub 2015 Jun 22. N Engl J Med. 2015. PMID: 26095467 Clinical Trial.
-
A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism.Thromb Res. 2012 Jan;129(1):22-7. doi: 10.1016/j.thromres.2011.06.025. Epub 2011 Jul 29. Thromb Res. 2012. PMID: 21802118 Free PMC article.
-
Occult cancer and thromboembolism: current epidemiology and its practical implications.Pol Arch Intern Med. 2018 Sep 28;128(9):539-544. doi: 10.20452/pamw.4311. Epub 2018 Jul 27. Pol Arch Intern Med. 2018. PMID: 30057385 Review.
-
Venous thromboembolism and occult cancer: impact on clinical practice.Thromb Res. 2016 Apr;140 Suppl 1:S8-11. doi: 10.1016/S0049-3848(16)30091-3. Thromb Res. 2016. PMID: 27067984 Review.
Cited by
-
Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.Cochrane Database Syst Rev. 2018 Nov 8;11(11):CD010837. doi: 10.1002/14651858.CD010837.pub4. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2021 Oct 1;10:CD010837. doi: 10.1002/14651858.CD010837.pub5. PMID: 30407621 Free PMC article. Updated.
-
Cancer Screening in Patients with Unprovoked Thromboembolism: How to do it and Who Benefits?Cureus. 2020 Feb 10;12(2):e6934. doi: 10.7759/cureus.6934. Cureus. 2020. PMID: 32051805 Free PMC article.
-
Cancer-associated thrombosis: the when, how and why.Eur Respir Rev. 2019 Mar 27;28(151):180119. doi: 10.1183/16000617.0119-2018. Print 2019 Mar 31. Eur Respir Rev. 2019. PMID: 30918022 Free PMC article. Review.
-
Occult cancer detection in venous thromboembolism: the past, the present, and the future.Res Pract Thromb Haemost. 2017 Jun 16;1(1):9-13. doi: 10.1002/rth2.12007. eCollection 2017 Jul. Res Pract Thromb Haemost. 2017. PMID: 30046669 Free PMC article. Review.
-
Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.Cochrane Database Syst Rev. 2021 Oct 1;10(10):CD010837. doi: 10.1002/14651858.CD010837.pub5. Cochrane Database Syst Rev. 2021. PMID: 34597414 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical